Approval decisions are due for Jazz, Gilead and Galapagos in July, while Glaxo is preparing for a panel.
June will be hectic for the US regulator, with many approval decisions due, including one for subcutaneous Arzerra in multiple sclerosis and Tazverik in follicular…
Spending $95m to speed up the anaemia project’s path to approval could be worth the investment for Astrazeneca.
Curevac’s decision to exit work on an mRNA approach to OTC deficiency follows a clinical hold on Translate Bio’s similar project, and raises broader concerns.
The Australian group has found a partner for its lead asset at last, so why is the stock down?